Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Comment by Mercuryfilling1on Apr 08, 2022 5:15pm
157 Views
Post# 34589376

RE:Melton off to Vertex

RE:Melton off to Vertex
BioTeck wrote: https://www.biospace.com/article/harvard-researcher-heads-to-vertex-to-curate-diabetes-portfolio/




Bringing in an expensive pinch hitter doesn't guarantee you a world series title.
Melton will be just as constrained as Witkowski by all the protocols, safety concerns, finding patients etc. This will be a slow crawl (whether partnered or separately) to the finish line, not a mad dash. Vertex published "positive" 90 day data for their 1st patient in October last year. The results were called "unprecedented" and "truly remarkable". Okay, so they own a better thesaurus than SVA and have a ton of money (one billion for Semma). But it's still a phase1/2 study with 2028 being the completion date. Do I want Dr. T to sell out for a three dollar bill? Not really.

https://clinicaltrials.gov/ct2/show/NCT04786262?term=VX-880&draw=2&rank=1


<< Previous
Bullboard Posts
Next >>